 The investigator evaluated the safety and immunogenicity for each subject throughout the study. Safety assessments were performed 28 days after the first dose Visit 4, End-of-Study Visit for the comparator group receiving a single-dose regimen of Fluarix Prefilled Syringe, and for the test group receiving a two-dose regimen of the test drug, 28 days after the first dose Visit 4 and 28 days after the second dose Visit 6, End-of-Study Visit. Subjects were instructed to record any adverse event occurring after vaccination in the Patient Diary Card. For the immunogenicity assessment, an antibody titer test was performed prior to dosing at Visit 2 baseline and 28 days Visit 4 after the first vaccination for both the test group and comparator group. 